Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE)

Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE)

BackgroundIn this single-arm study, the efficacy and safety of neoadjuvant pembrolizumab plus chemotherapy were evaluated in patients with resectable esophageal squamous cell carcinoma (ESCC).MethodsThis study included patients with ESCC of clinical stages II–IVA who underwent surgery within 4 to 6...

Full description

Bibliographic Details
Main Authors: Hongtao Duan, Changjian Shao, Minghong Pan, Honggang Liu, Xiaoping Dong, Yong Zhang, Liping Tong, Yingtong Feng, Yuanyuan Wang, Lu Wang, Neil B. Newman, Inderpal S. Sarkaria, John V. Reynolds, Francesco De Cobelli, Zhiqiang Ma, Tao Jiang, Xiaolong Yan
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Immunology
Subjects:
Pembrolizumab
chemotherapy
resectable esophageal cancer
efficacy
safety
pathological complete response (pCR)
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.849984/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.849984/full

Similar Items